Resource Center

More to Explore - Information About Blood Cancers for Patients, Families and Healthcare Professionals

The Word:


November 14, 2012 - Myeloma - Diagnosis and Treatment Update

Your order contains  item(s)  View Order

Note: The free Adobe Acrobat Reader® is required to view and print Adobe PDF files, and the free Windows Media Player or RealPlayer is required to listen to the MP3 audio files.

Date: November 14, 2012
Time: 12:30 p.m. - 2:00 p.m. ET
Location: Telephone/Web
View: Program Slides 
Read: Myeloma News | Transcript
Listen: Presentation | Q&A Session
Access: Virtual Lecture

Topics Covered

  • Goals of myeloma treatment
  • Current treatments and emerging therapies, including updates on stem cell transplantation and maintenance therapy
  • Updates on side effects management
  • The importance of patient and healthcare team communications


Ruben Niesvizky,MD
Director, Multiple Myeloma Center
Associate Attending Physician
Division of Hematology/Oncology
Weill Medical College of Cornell University
New York, New York

Questions Asked by the Myeloma Community

  • Is it possible to start treatment for myeloma too soon?
  • Would starting treatment too soon hinder any chances of reaching remission?
  • What is the difference between lytic lesions and osteoblastic lesions?
  • Can you please tell use what criteria determine a complete response and does this vary among different treatment specialists?
  • Is there anything diet or exercise-wise that will dramatically impact how well a patient is doing with the disease?
  • Does foot neuropathy go away?
  • Is bortezomib (Velcade®) a medicine that can help myeloma or is there another choice?
  • Do patients who have a stem cell transplant early, as opposed to lenalidomide (Revlimid®) or some other drug therapy, generally have a better outcome?
  • Does taking dexamethasone cause blurry eyes? Would another steroid be a better choice that would help this side effect and also still help treat myeloma?
  • Do the topics today focus primarily on older patients or are they also for younger patients?
  • Can hot flashes and extreme itching be side effects of multiple myeloma?
  • How can someone living in a remote or rural area and unable to travel get the best available treatment and research advances in their home community?
  • How can a patient's community physician link up with a treatment or research center?
  • After a Velcade and dexamethasone regimen and a stem cell transplant, should a patient be on maintenance or wait for symptoms to reoccur?
  • Please discuss secondary cancers with lenalidomide (Revlimid®) maintenance.
  • After being off Revlimid for five months, how long will the side effects continue and will they ever go away?
  • Is it okay to take etanercept (Enbrel®) for rheumatoid arthritis after also being diagnosed with multiple myeloma?
  • What information is available about the genetic nature of multiple myeloma?
  • What is the role of free light chain criteria in determining when to start treatment?

Sponsors and Supporters

This program is sponsored by The Leukemia & Lymphoma Society and supported by grants from Celgene Corporation, Millennium: The Takeda Oncology Company, and Onyx Pharmaceuticals, Inc.

last updated on Tuesday, April 15, 2014

Get Information
& Support

Contact an Information Specialist.